Xtandi is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.
Resitance to xtandi therapy has been observed. This may occurred due to an upregulation of NF-κB2/p52.
The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.
Strength: 40 Mg
Pill Imprint: ENZ
Shape: Elliptical / Oval
View Images & Details